triocean | Adobe Stock
The U.S. Food & Drug Administration (FDA) approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages 1 through 3 years with a confirmed diagnosis of peanut allergy to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.
Palforzia has been approved since January 2020 for initiation of treatment in individuals ages 4 through 17 years with a confirmed diagnosis of peanut allergy with up-dosing and maintenance in individuals 4 years of age and older.
Those who take Palforzia must continue to avoid peanuts in their diets. A Risk Evaluation and Mitigation Strategy (REMS) is in place for Palforzia to mitigate the risk of anaphylaxis associated with Palforzia, which includes elements to assure safe use.
Latest from Quality Assurance & Food Safety
- Kraft Heinz Hosts Innovation Challenge for Sustainable Packaging
- FDA Requests Information on Poppy Seeds
- Danone North America Opens Applications for Annual Gut Microbiome, Yogurt and Probiotics Fellowship Grant
- WSDA Confirms First Bird Flu Case in 2025
- Senators Call Out FDA for Proposed Cuts to State, Local Food Safety Programs
- FSIS Cites Inadequate Sanitation as Contributing Factor to Boar’s Head Listeria Outbreak
- Ineo Oxford Institute Professor Receives Wellcome Discovery Award to Develop Campylobacter Vaccine for Livestock
- International Fresh Produce Association Expands Food Safety Team
